Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20959395 | 0.79 | NPC1 (0.36) | F10RAB9A | |
| SCHEMBL20959117 | 0.78 | F10 (0.36) | F10 | |
| SCHEMBL20958741 | 0.76 | F10 (0.39) | F10ALDH1A1KMT2A | |
| SCHEMBL20959070 | 0.75 | F10 (0.38) | F10RAB9AALDH1A1KMT2A | |
| SCHEMBL20958793 | 0.74 | PDE7A (0.36) | F10NPY5R | |
| SCHEMBL20959484 | 0.74 | PDE7A (0.38) | NPY5RALDH1A1 | |
| SCHEMBL28376375 | 0.71 | CDA (0.39) | CDAL3MBTL1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL20959062 | 0.70 | CDA (0.38) | CDAL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL19271812 | 0.70 | CDA (0.42) | CDAF10L3MBTL1NPY5RALDH1A1 | |
| SCHEMBL28887268 | 0.70 | CDA (0.36) | CDAL3MBTL1NPY5RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | HDAC6, HDAC1, HDAC5 | CDA 4632/4885F10 4590/4885CCR2 3430/4885 |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC5, HDAC6 | CDA 4339/4885F10 4461/4885CCR2 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.